Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-08-10
Item 5.02
The filing discloses the appointment of Eric Williams as Executive Vice President of Engineering, effective August 31, 2026. While the disclosure also includes compensatory arrangements (base salary of $400,000 and 40% target bonus), the principal action is the appointment of a named executive officer with significant prior experience (three decades of advanced reactor engineering leadership from TerraPower). The appointment of a senior executive to a newly-filled or newly-created role is material to investors assessing the company's leadership and operational capacity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-10
Item 8.01
The Company filed a prospectus supplement on August 10, 2026 to offer and sell up to $400,000,000 of shares of common stock under an at-the-market (ATM) offering agreement with Guggenheim Securities. This is a material dilutive equity issuance that would affect a reasonable investor's assessment of ownership dilution and capital structure, particularly given the substantial size ($400 million) of the offering.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-10
Item 1.01
MPT closed a material debt transaction on August 10, 2026, issuing $2.4 billion in aggregate principal amount of new 9.25% senior secured notes due 2032 through a private placement and exchange. The transaction also refinanced approximately $1.5 billion of existing unsecured notes and funded redemptions of senior notes due 2026 and 2027.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-10
Item 1.01
Stellex Capital Management acquired all 1,604,326 shares (approximately 35% of outstanding common stock) held by Corre Partners at $35.50 per share, becoming the largest common equity shareholder and effecting a material change of control in the Company's equity structure and voting control.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-10
Item 8.01
Sunstone Hotel Investors entered into an equity distribution agreement on August 10, 2026, authorizing the issuance and sale of up to $300 million in common stock shares through multiple sales agents and forward sale agreements. The filing explicitly describes an "at-the-market offering" program with forward contracts that will result in dilution to existing shareholders. This is a material capital-raising transaction typical of dilutive issuances under Item 3.02, though disclosed here under Item 8.01.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-10
EX-99.1
BMO announced the sale of its 50% stake in jointly-owned Moneris Solutions Corporation to Francisco Partners for approximately $1.0 billion (BMO's share of $2.0 billion total), with an expected after-tax gain of $600 million and a 15 bps improvement to CET1 ratio. This is a material disposition of a significant asset that materially affects the registrant's financial position and capital structure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Item 2.02 discloses Apollo Commercial Real Estate Finance's financial results for the quarter ended June 30, 2026, with a summary press release and detailed presentation attached as exhibits. The filing reports net income of $0.11 per diluted share, Distributable Earnings metrics, and significant portfolio activity including the completed sale of the company's commercial real estate loan portfolio to Athene Holding Ltd. This is a standard quarterly earnings release disclosure material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
EagleRock issued a press release on August 10, 2026 disclosing financial results for the quarter ended June 30, 2026, including revenue of $41.5 million, normalized revenue of $46.8 million (up 32.3% QoQ), normalized adjusted EBITDA of $36.2 million, and full-year 2026 guidance of $129–$133 million normalized EBITDA.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-10
Item 2.03
Churchill Capital Corp XI issued an unsecured promissory note of up to $1,500,000 to its sponsor for working capital needs. Although the note is convertible into equity units at the sponsor's option, the primary transaction is the creation of a direct financial obligation constituting a debt issuance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a straightforward earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that "Oruka Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated balance sheets and statements of operations showing Q2 2026 results (net loss of $41.2 million vs. $24.6 million in Q2 2025) along with a corporate update on pipeline progress.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-10
EX-99.1
This is a press release disclosing unaudited financial results for Q2 2026 (quarter ended June 30, 2026), including revenue of US$228.8 million, net loss of US$92.3 million, and Adjusted EBITDA of US$31.1 million. The document explicitly states "Bitdeer Reports Unaudited Financial Results for the Second Quarter of 2026" and provides detailed P&L, operational metrics, and MD&A analysis typical of a quarterly earnings release. Material to investors assessing the registrant's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
MoonLake disclosed second quarter 2026 financial results via press release dated August 10, 2026, reporting cash position of $537.0 million, R&D expenses of $50.2 million, G&A expenses of $11.4 million, and cash runway to mid-2028. The press release also announced positive topline Week 16 results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all clinical endpoints.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-10
EX-99.1
This press release announces TOYO's strategic response to President Trump's Section 232 proclamation on solar manufacturing, including the company's commitment to expand U.S. manufacturing operations (a $357 million HJT cell facility in Texas, a 2GW module facility in Houston, and planned polysilicon-to-module supply chain development). While the disclosure involves regulatory/trade policy context, the core event is TOYO's operational and strategic business commitment to accelerate domestic manufacturing investment and engage with the Department of Commerce on an integrated manufacturing plan. This is a material operational/strategic announcement affecting the company's capital allocation and growth trajectory, but does not fit the specific categories of M&A, debt issuance, workforce reduction, or other named event types.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-10
EX-99.1
Alpha Tau announced its intention to register for dual listing on the Tel Aviv Stock Exchange (TASE) alongside its existing Nasdaq listing. This is a material strategic and operational milestone—a significant capital markets event affecting where and how the company's shares trade—but does not fit the specific event-type taxonomy (not M&A, not a delisting risk, not a dilutive issuance, not a periodic report). The press release explicitly states the company "has requested to register" shares and expects them to trade on TASE under symbol DRTS, making this a discrete operational/strategic event rather than a routine administrative disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
This is a straightforward earnings release for Jerash Holdings' fiscal 2027 first quarter ended June 30, 2026. The filing discloses record revenue of $50.2 million (up 26.7%), gross profit of $8.3 million (up 35.7%), and net income of $1.7 million (up more than fivefold), along with detailed financial statements and forward guidance. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-08-10
Item 3.01
Faraday Future received written notice from Nasdaq on August 7, 2026, confirming that the Company has regained compliance with Listing Rule 5550(a)(2) after its Common Stock closing bid price remained at $1.00 per share or greater for 10 consecutive business days (July 24–August 6, 2026), formally closing the related compliance matter.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-10
The filing discloses the appointment of Kenji Konishi as Head of Magnet Engineering Production, a senior operational leadership role. The press release emphasizes his decades of experience scaling rare earth magnet production and notes he is joining with "a team of senior engineers," positioning this as a material executive appointment critical to the company's expansion toward 10,000 metric tons of annual capacity by November 2026 and DFARS compliance by January 1, 2027.
View raw filing on EDGAR →
6-K
M&A activity
confidence 75%
filed 2026-08-10
The 6-K discloses entry into a material colocation lease and services agreement between Bitdeer subsidiary Tydal Data Center AS and Volta Tydal AS, with a total contract value of approximately $4.7 billion over 16 years (potentially $8.0 billion with renewal options). This represents a significant long-term revenue-generating arrangement with substantial capacity commitments (121 IT MW) and capital requirements (~$500 million remaining capex), constituting a material operational and financial commitment that would affect investor assessment of the company's growth strategy and cash flows.
View raw filing on EDGAR →
6-K
Governance Other
confidence 75%
filed 2026-08-10
The 6-K discloses multiple governance events: (1) resignation of two directors (Ms. Lurie and Mr. Wagner) and appointment of four new directors (Vardi, Adler, Kabazo, Revach) following a shareholder dispute settlement; (2) entry into a Cooperation Agreement resolving a demand letter and court proceedings over board composition; and (3) a financing commitment from a shareholder. While the filing contains both exec_departure and exec_appointment elements, the primary disclosed action is the settlement of a shareholder dispute and restructuring of board composition through a cooperation agreement, which is fundamentally a governance matter that does not fit neatly into the specific appointment or departure categories alone. The material nature is clear given the contested board changes, litigation settlement, and shareholder control implications.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-10
Item 5.07
This Item 5.07 disclosure reports the results of OSR Health's August 7, 2026 annual stockholder meeting, including the re-election of seven directors, ratification of the independent auditor, approval of executive compensation, and authorization of additional shares. The filing presents voting tallies for each proposal, which is the core content of a shareholder vote results disclosure. These outcomes are material to investors as they confirm board composition, auditor retention, and capital structure changes.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including net revenue of $51 thousand, operating expenses, and net loss of $7.3 million, along with key operational milestones (FDA PMA submission, clinical trial data). The filing includes condensed consolidated balance sheets and is material to investors assessing the company's financial position and progress toward commercialization of its Acclaim cochlear implant.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-10
EX-99.3
This is a press release dated August 10, 2026, announcing Alpha Tau's second quarter 2026 financial results, including R&D expenses of $20.9M, net loss of $68.8M ($0.76 per share), and cash balance of $104.8M. The release also discloses significant clinical and corporate milestones (REGAIN glioblastoma trial results, ReSTART enrollment completion, Tolmar partnership with $20M equity investment and $161.5M in milestone payments). While the exhibit bundles multiple announcements, the primary disclosure is the quarterly financial results with accompanying operational updates, making this an earnings release.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-10
EX-99.1
This is a corporate presentation detailing Purple Biotech's CAPTN-3 tri-specific antibody platform and pipeline progress, including preclinical data for lead program IM1240 and second program IM1305. The exhibit discloses material operational and strategic milestones: completion of non-human primate toxicology studies, IND submission planned for 2027, Phase 1 initiation expected in H1 2027, and a pre-IND meeting with a clear development roadmap. These represent significant operational progress toward clinical development of novel oncology therapeutics, constituting a material business update on product development strategy and near-term catalysts.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-10
Item 2.02
RUM Group Inc. issued a press release on August 10, 2026 announcing Q2 2026 financial results with record quarterly revenue of $40.4 million (up 61% year-over-year), detailed expense information, and initiated Q3 2026 revenue guidance of $87–$93 million.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-10
The 6-K announces the appointment of Daniel Brau as Chief Quantum Officer of SEALSQ effective August 4, 2026, following the Company's acquisition of Miraex SA. The disclosure includes detailed biographical information, his prior role as CEO of the acquired company, and his new responsibilities overseeing the quantum technology portfolio and strategic partnerships. This is a material executive appointment tied to a significant acquisition integration.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-10
The filing discloses entry into a definitive Equity Purchase Agreement on August 10, 2026, for Proficient Auto Logistics to acquire Hansen & Adkins Auto Transport for approximately $130 million in total consideration (including $75 million in assumed debt, $3 million in stock, and $52 million in cash, plus potential earnouts up to $22.1 million). This is a material acquisition transaction disclosed under Item 1.01, representing a significant M&A activity that would materially affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.6 million (up from $61 thousand in Q2 2025), net loss of $11.8 million, and key operational metrics. The filing includes condensed consolidated statements of operations and balance sheets as exhibits, which are standard components of an earnings disclosure. This is material to investors as it reports the company's financial performance and position.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-10
EX-99.1
The press release announces the appointment of André Cazotto as Chief Financial Officer of PicPay, effective immediately, succeeding Rodrigo Couto who transitions to Special Advisor. This is a material executive appointment at the C-suite level (CFO) at a recently IPO'd company (January 2026), and the disclosure explicitly details Cazotto's qualifications and his expanded responsibilities overseeing financial operations, investor relations, strategy, and M&A.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-10
Item 3.02
SunPower Inc. entered into a SAFE (Simple Agreement for Future Equity) with an institutional investor for $3.5 million, convertible into equity securities at the price of the Company's next equity financing. This unregistered sale of equity securities, relying on Section 4(a)(2) exemption, will materially dilute existing shareholders upon conversion.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-10
Item 1.01
Pinnacle Acquisition Corporation completed its IPO on August 6, 2026, issuing 20,000,000 units at $10.00 per unit for $200 million in gross proceeds, with the Underwriting Agreement with Santander and Private Placement Units Purchase Agreement with the Sponsor constituting material capital-raising agreements.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-10
Item 3.02
The Sponsor purchased 225,000 private placement units at $10.00 per unit ($2.25 million aggregate) pursuant to Section 4(a)(2) exemption, completed simultaneously with the IPO closing.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-10
Item 5.02
Four directors—Andrew Rechtschaffen, Karen Martin, Paul Stoyan, and Harry Brandler—were appointed to the board in connection with the IPO on August 6, 2026, with assignments to specific board committees.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-08-10
Item 5.03
Amended and restated memorandum and articles of association were filed with the Cayman Islands Registrar in connection with the IPO, effective August 6, 2026, reflecting the company's transition to public company status.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-08-10
The 6-K discloses a grant of 1,000,000 ordinary shares on August 4, 2026, pursuant to the Company's 2026 Omnibus Equity Plan to officers and employees, including 200,000 shares to CEO Yi Shao and 200,000 shares to CFO Lijuan Ding. This is a direct disclosure of equity compensation arrangements for named executives, which falls squarely within the exec_compensation category. The grants vested immediately and were formalized through Unrestricted Stock Award Agreements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-10
Item 2.02
Kayne Anderson BDC reported quarterly financial results for the period ended June 30, 2026, including net investment income of $27.5 million ($0.42 per share) and net asset value of $16.00 per share, along with portfolio metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-10
Item 2.02
Purple Innovation issued a press release on August 10, 2026, announcing Q2 2026 financial results (net revenue of $98.3 million, GAAP net loss of $3.2 million, adjusted EBITDA of $2.1 million) and revised full-year 2026 revenue guidance to $420–$440 million. This is a standard quarterly earnings disclosure under Item 2.02, with the press release furnished as Exhibit 99.1.
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-08-10
EX-99.1
SAIHEAT has entered into a definitive merger agreement with Canopy Wave, Inc., dated August 10, 2026, whereby Canopy Wave will become a wholly-owned subsidiary and the combined company will be renamed "Canopy Wave Holdings Inc." and trade under ticker "CWAV." This is a material acquisition/merger transaction with clear strategic rationale (pivoting into AI inference infrastructure), specified valuations ($60M for Canopy Wave, $40M for SAIHEAT), and defined ownership structure (former Canopy Wave shareholders owning ~54% economic and ~78% voting interests post-closing). The transaction is subject to customary closing conditions including shareholder approval and Nasdaq listing approval, with expected closing by end of 2026.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-10
Item 8.01
This disclosure reports shareholder approval of a new investment sub-advisory agreement between the Trust, its adviser XA Investments, and Rockford Tower Asset Management (King Street Sub-Adviser), executed on August 10, 2026 following a reconvened special meeting on August 6, 2026. While the filing is under Item 8.01 (Other Events) rather than Item 5.07 (shareholder vote results), the core event is governance-related—approval and execution of a material advisory contract. This is material to investors as it affects the Trust's investment management structure and terms, though it does not fit the specific shareholder_vote_results category (which typically emphasizes the vote outcome itself rather than the subsequent contract execution).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 94%
filed 2026-08-10
Item 5.07
Shareholders approved an amendment to the Company's Articles of Association extending the deadline for completing an initial business combination from August 8, 2026 to August 8, 2027, and approved an adjournment proposal at an extraordinary general meeting held on August 4, 2026. Additionally, shareholders exercised redemption rights for 12,863,312 Class A ordinary shares, resulting in approximately $135.2 million being removed from the trust account and $15.9 million remaining.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-10
Item 1.01
On August 10, 2026, the Company entered into an Amendment, Waiver and Warrant Cancellation Agreement with White Lion Capital LLC that materially restructures its existing financing arrangements, including cancellation of 2,612,822 warrant shares, termination of the right to a fifth closing under the Note Purchase Agreement, and amendment of the stockholder approval deadline to September 30, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-10
Item 2.03
The Company issued a Convertible Note with a face amount of $555,556 in the Fourth Closing on July 10, 2026, receiving $500,000 in net cash proceeds, creating a new direct financial obligation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-10
Item 3.03
Tenon Medical implemented a 1-for-35 reverse stock split effective August 10, 2026, to meet Nasdaq's minimum $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market. The reverse split was undertaken in direct response to delisting risk and represents a material event affecting the company's exchange listing status.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-10
Highway Holdings has signed a master agreement to form a majority-owned (57%) joint venture with Guangdong Huahu New Energy Technology Co., Ltd., representing a material acquisition and change of control event. The transaction involves Highway Holdings contributing approximately $2.0 million in cash plus equity incentives (up to 400,000 restricted shares), gaining control of a new operating entity in the fast-growing battery energy storage market, and establishing a strategic platform for business diversification and manufacturing expansion.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-08-10
Item 1.01
On August 4, 2026, the Company entered into an Amendment Agreement materially amending the Stock Purchase Agreement with General Alpha Ltd. dated May 29, 2025. The Amendment extends the expiration date to August 3, 2028, modifies anti-dilution protections, removes certain review provisions, and adds new deduction rights for the Purchaser, materially affecting the Company's capital structure and obligations.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-08-10
EX-99.1
This is a notice and proxy statement for an extraordinary general meeting scheduled for August 20, 2026, soliciting shareholder votes on three proposals: (1) a 50-for-1 share consolidation, (2) adoption of amended memorandum and articles of association, and (3) meeting adjournment. While the document is dated August 10, 2026 (before the meeting), it is being furnished as an exhibit to a 6-K filed on August 10, 2026, and constitutes the formal disclosure of shareholder voting matters. The share consolidation is a material capital structure change affecting all shareholders. However, this is technically a pre-meeting notice rather than post-meeting results; the classification as shareholder_vote_results is the closest fit in the taxonomy for material shareholder voting disclosures, though the results themselves are not yet known at filing date.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-10
The filing discloses the appointment of Wesley Batista Filho as Global CEO effective January 2027, alongside the concurrent departure of Gilberto Tomazoni. While both events occur, the principal action announced is Batista Filho's appointment to the top executive role. The filing emphasizes his appointment and career trajectory at JBS, making this the salient event, though the concurrent CEO transition is also material.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-08-10
EX-99.1
RBC announced entry into an agreement for the sale of its 50% stake in Moneris Solutions Corporation to Francisco Partners for approximately $1 billion in cash consideration. The press release explicitly states RBC "has entered into an agreement for the sale" and discloses a material after-tax gain of approximately $475 million, expected closing by Q1 fiscal 2027, and positive impact to CET1 ratio. This is a material disposition of a jointly-owned subsidiary meeting the definition of M&A activity under Item 1.01/2.01.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-08-10
EX-99.1
This news release discloses the voting results from Aurora Cannabis Inc.'s Annual General Meeting of Shareholders held August 7, 2026. The exhibit provides detailed voting tallies for five board nominees (Miguel Martin, Michael Singer, Chitwant Kohli, Norma Beauchamp, and Rajesh Uttamchandani), approval of Ernst & Young LLP as auditors, and a "Say-on-Pay" advisory vote on executive compensation (82.97% FOR). This is a classic shareholder_vote_results disclosure reporting the outcomes of an annual meeting election and resolutions.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-08-10
EX-99.1
This exhibit is a formal report of voting results from Aurora Cannabis Inc.'s annual general meeting of shareholders held on August 7, 2026, disclosing the outcomes of four shareholder votes: (1) fixing the number of directors at five, (2) election of five directors by name, (3) appointment of Ernst & Young LLP as auditors, and (4) an advisory say-on-pay vote on executive compensation. The document explicitly states it is filed "Pursuant to Section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations," which is the Canadian equivalent of Item 5.07 (Results of Shareholder Votes). These governance outcomes are material to investors assessing the company's leadership and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-10
Item 5.02
The disclosure centers on the Board's appointment of Anthony W. Boor as a new Class A director on August 5, 2026. Although the filing also describes his existing role as Executive Vice President of Corporate Development and Strategy and references his retention agreement with compensation details, the principal disclosed action is his election to the Board. This is a material governance event affecting the composition of the registrant's board of directors.
View raw filing on EDGAR →